» Articles » PMID: 27447722

Methylsulfonylmethane Inhibits RANKL-Induced Osteoclastogenesis in BMMs by Suppressing NF-κB and STAT3 Activities

Overview
Journal PLoS One
Date 2016 Jul 23
PMID 27447722
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Osteoclast differentiation is dependent on the activities of receptor activator NF-kB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF). Given that RANKL plays a critical role in osteoclast formation and bone resorption, any new compounds found to alter its activity would be predicted to have therapeutic potential for disorders associated with bone loss. Methylsulfonylmethane (MSM) is a naturally occurring sulfur compound with well-documented anti-oxidant and anti-inflammatory properties; currently its effects on osteoclast differentiation are unknown. We sought to investigate whether MSM could regulate osteoclastogenesis, and if so, its mechanism of action. In this study, we investigated the effects of MSM on RANKL-induced osteoclast differentiation, together with STAT3's involvement in the expression of osteoclastic gene markers. These experiments were conducted using bone marrow derived macrophages (BMMs) and cell line material, together with analyses that interrogated both protein and mRNA levels, as well as signaling pathway activity. Although MSM was not toxic to osteoclast precursors, MSM markedly inhibited RANKL-induced TRAP activity, multinucleated osteoclast formation, and bone resorptive activity. Additionally, the expression of several osteoclastogenesis-related marker genes, including TRAF6, c-Fos, NFATc1, cathepsin K, and OSCAR were suppressed by MSM. MSM mediated suppression of RANKL-induced osteoclastogenesis involved inhibition of ITAM signaling effectors such as PLCγ and Syk, with a blockade of NF-kB rather than MAPK activity. Furthermore, MSM inhibited RANKL-induced phosphorylation of STAT3 Ser727. Knockdown of STAT3 using shRNAs resulted in reduced RANKL-mediated phosphorylation of Ser727 STAT3, and TRAF6 in cells for which depletion of STAT3 was confirmed. Additionally, the expression of RANKL-induced osteoclastogenic marker genes were significantly decreased by MSM and STAT3 knockdown. Taken together, these results indicate that STAT3 plays a pivotal role in RANKL-induced osteoclast formation, and that MSM can attenuate RANKL-induced osteoclastogenesis by blocking both NF-kB and STAT3 activity.

Citing Articles

Protective Effect of Methyl Sulfonyl Methane on the Progression of Age-Induced Bone Loss by Regulating Oxidative Stress-Mediated Bone Resorption.

Zhang D, Wang L, Tang L, Zhang Y, Zhang H, Zou L Antioxidants (Basel). 2025; 14(2).

PMID: 40002402 PMC: 11851857. DOI: 10.3390/antiox14020216.


The Metabolic Profile of Plasma During Epileptogenesis in a Rat Model of Lithium-Pilocarpine-Induced Temporal Lobe Epilepsy.

Antmen F, Matpan E, Dayanc E, Savas E, Eken Y, Acar D Mol Neurobiol. 2025; .

PMID: 39904962 DOI: 10.1007/s12035-025-04719-6.


Drug protection against radiation-induced neurological injury: mechanisms and developments.

Wang Q, Guo C, Wang T, Shuai P, Wu W, Huang S Arch Toxicol. 2024; 99(3):851-863.

PMID: 39724149 DOI: 10.1007/s00204-024-03933-w.


Pro-Osteogenic Effect of the Nutraceutical BlastiMin Complex in Women with Osteoporosis or Osteopenia: An Open Intervention Clinical Trial.

Sabatelli S, Scarpa E, Giuliani A, Giordani C, Sabbatinelli J, Rippo M Int J Mol Sci. 2024; 25(16).

PMID: 39201253 PMC: 11354786. DOI: 10.3390/ijms25168565.


Methylsulfonylmethane Improves Knee Quality of Life in Participants with Mild Knee Pain: A Randomized, Double-Blind, Placebo-Controlled Trial.

Toguchi A, Noguchi N, Kanno T, Yamada A Nutrients. 2023; 15(13).

PMID: 37447322 PMC: 10346176. DOI: 10.3390/nu15132995.


References
1.
Duplomb L, Baudhuin M, Charrier C, Berreur M, Trichet V, Blanchard F . Interleukin-6 inhibits receptor activator of nuclear factor kappaB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine727 phosphorylation of signal transducer and activator of transcription 3. Endocrinology. 2008; 149(7):3688-97. DOI: 10.1210/en.2007-1719. View

2.
Park H, Noh A, Kang J, Sim J, Lee D, Yim M . Peroxiredoxin II negatively regulates lipopolysaccharide-induced osteoclast formation and bone loss via JNK and STAT3. Antioxid Redox Signal. 2014; 22(1):63-77. PMC: 4270137. DOI: 10.1089/ars.2013.5748. View

3.
Li C, Zhao J, Sun L, Yao Z, Deng X, Liu R . AG490 inhibits NFATc1 expression and STAT3 activation during RANKL induced osteoclastogenesis. Biochem Biophys Res Commun. 2013; 435(4):533-9. DOI: 10.1016/j.bbrc.2013.04.084. View

4.
Boyle W, Simonet W, Lacey D . Osteoclast differentiation and activation. Nature. 2003; 423(6937):337-42. DOI: 10.1038/nature01658. View

5.
Monje P, Hernandez-Losa J, Lyons R, Castellone M, Gutkind J . Regulation of the transcriptional activity of c-Fos by ERK. A novel role for the prolyl isomerase PIN1. J Biol Chem. 2005; 280(42):35081-4. DOI: 10.1074/jbc.C500353200. View